PCa is usually diagnosed by a combination of different methods, digital rectal examination (DRE), a blood test to measure prostate-specific antigen (PSA) levels, and transrectal ultrasound-guided (TRUS) prostate biopsy, which provides the final confirmation. This evidence concerns the gene KLK3 and posterior cortical atrophy.